EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Growth Hormone-Releasing Hormone (GHRH) Antagonist Peptides Combined with PI3K Isoform Inhibitors Enhance Cell Death in Prostate Cancer

Carlos Perez-Stable, Alicia de Las Pozas, Medhi Wangpaichitr iD, Wei Sha iD, Haibo Wang, Renzhi Cai, Andrew V Schally iD

Cancers · 13.05.2025 · 17 (10) · 1643

DOI: 10.3390/cancers17101643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 13.05.2025. Verfasst von Carlos Perez-Stable und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Service, Bruce W. Carter Veterans Affairs Medical Center, Miami, FL 33125, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, United States Department of Veterans Affairs, Veterans Affairs BLR&D Distinguished Medical Research Scientist Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antagonists of GHRH have experimental therapeutic value, but as single agents are not likely to improve clinical outcomes, especially in advanced prostate cancer resistant to androgen deprivation therapy. Our objective is to identify anti-cancer drugs that, in combination with MIA-602 or -690 GHRH antagonists, increase cell death in all types of prostate cancer. Methods/Results. We identified inhibitors of PI3Kα or PI3Kβ that consistently increased cell death when combined with MIA-602/690. The PI3K family is critical in mediating upstream signals from receptors to downstream AKT/mTOR signaling pathways and has an important role in cancer progression. The results revealed that MIA-602/690 alone decreased androgen receptors and likely enhanced PI3K (negative feedback), which was then countered by the addition of PI3K inhibitors. Furthermore, the MIA-602/690 + PI3K inhibitor combination affected multiple signaling pathways, including apoptosis (anti-apoptotic Mcl-1L switching to pro-apoptotic Mcl-1S), proliferation (E2F1, cyclin A), PI3Kα/β, AKT, and ERK. Similar results were obtained with a more clinically relevant acetate salt form of MIA-602/690. The identification of PI3K as a drug target for prostate cancer is significant because PTEN (negative regulator of PI3K) loss of function occurs in 40–50% and PIK3CA mutation/amplification occurs in 60% of prostate cancer patients, leading to a poor prognosis.

Conclusion

The ability of the MIA-602/690 + PI3K inhibitor combination to alter multiple signaling pathways may weaken the activation of adaptive mechanisms resulting from each drug and improve efficacy.

Schlagwörter

Stichwörter der Autor:innen

AKTERKMcl-1PI3Kandrogen receptorgrowth hormone-releasing hormone antagonistprostate cancer

Autor:innen und Institutionen

  • Research Service, Bruce W. Carter Veterans Affairs Medical Center, Miami, FL 33125, USA.
  • Geriatric Research, Education, and Clinical Center, Bruce W. Carter Veterans Affairs Medical Center, Miami, FL 33125, USA.
  • Division of Gerontology & Palliative Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • South Florida VA Foundation for Research and Education, Miami, FL 33125, USA.

ORCID-Profile: Medhi Wangpaichitr, Wei Sha, Andrew V Schally

Förderung

  • BLRD VA
  • United States Department of Veterans Affairs
  • Veterans Affairs BLR&D Distinguished Medical Research Scientist Award
  • Miami VA Geriatric Research and Clinical Center (GRECC)

Zitieren

APA

Perez-Stable, C., de Las Pozas, A., Wangpaichitr, M., Sha, W., Wang, H., Cai, R., & Schally, A. V. (2025). Growth Hormone-Releasing Hormone (GHRH) Antagonist Peptides Combined with PI3K Isoform Inhibitors Enhance Cell Death in Prostate Cancer. Cancers, 17(10), 1643. https://doi.org/10.3390/cancers17101643

Vancouver

Perez-Stable C, de Las Pozas A, Wangpaichitr M, Sha W, Wang H, Cai R, et al. Growth Hormone-Releasing Hormone (GHRH) Antagonist Peptides Combined with PI3K Isoform Inhibitors Enhance Cell Death in Prostate Cancer. Cancers. 2025;17(10):1643. doi:10.3390/cancers17101643

BibTeX
@article{PerezStable2025,
  author = {Perez-Stable, Carlos and de Las Pozas, Alicia and Wangpaichitr, Medhi and Sha, Wei and Wang, Haibo and Cai, Renzhi and Schally, Andrew V},
  title = {Growth Hormone-Releasing Hormone (GHRH) Antagonist Peptides Combined with PI3K Isoform Inhibitors Enhance Cell Death in Prostate Cancer},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {10},
  pages = {1643},
  doi = {10.3390/cancers17101643}
}
Kostenlos starten →